Posts from ‘August, 2009’

Genmab announces positive top-line results from the Phase II study of Arzerra in combination with CHOP in front line follicular NHL COPENHAGEN, Denmark, Aug. 26, 2009 –(HSMN NewsFeed) — Genmab A/S (Copenhagen:GEN ) announced today positive top-line re…
Biopharmaceuticals, Oncology
Genmab, Arzerra, ofatumumab, non-Hodgkin’s lymphoma

258 Patients, 40 Facilities to Participate in SUPERB Trial HOUSTON, Aug. 24 (HSMN NewsFeed) — IDEV® Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive clinical technologies, today announced…
Devices, Interventional
IDEV Technologies, SUPERA stent, SUPERB Trial, self-expanding stent

ATLANTA and BRIDGEWATER, N.J., Aug. 24 (HSMN NewsFeed) — UCB and sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved XYZAL® (levocetirizine dihydrochloride) for children age six months and older for the …
Biopharmaceuticals, FDA
UCB, sanofi-aventis, XYZAL, levocetirizine dihydrochloride

Findings Published in July Issue of the Journal of the American College of Radiology(1) SKILLMAN, N.J., Aug. 24 (HSMN NewsFeed) — ConvaTec, a world-leading provider of innovative pharma technologies for community and hospital care, today announced n…
Devices, Wound Care, Radiology
ConvaTec, AQUACEL Ag, antimicrobial dressing

New Drug Eluting Stent Offers Outstanding Combination of Deliverability, Safety and Efficacy ABBOTT PARK, Ill., Aug. 24 (HSMN NewsFeed) — Abbott (NYSE: ABT ) announced today that it has received approval from Health Canada for the XIENCE V(R) Everoli…
Devices, Interventional Cardiology, Regulatory
Abbott, XIENCE V, Everolimus, drug eluting stent

P&G Focuses on Winning in Consumer Health Care CINCINNATI and ARDEE, Ireland, Aug. 24, 2009 (HSMN NewsFeed) — The Procter & Gamble Company (NYSE: PG ) and Warner Chilcott plc (Nasdaq: WCRX ) today announced an agreement for the sale of P&G’s global p…
Biopharmaceuticals, Acquisitions
Procter & Gamble, Warner Chilcott

Tunable Algorithm Improves Results Accuracy VISTA, Calif.–(HSMN NewsFeed)–Aperio Technologies, Inc., (Aperio), a global leader in digital laboratory for the healthcare and life sciences industry, has received clearance from the U.S. Food and Drug Admin…
Diagnostics, Oncology, FDA
Aperio Technologies, digital laboratory, HER2, breast cancer

CASTLE ROCK, CO–(HSMN NewsFeed) - AspenBio Pharma, Inc. (NASDAQ:APPY ) reported it has received a request from the U.S. Food and Drug Administration ("FDA") for additional information related to AspenBio’s Premarket Notification 510(k) applicati…
Diagnostics, FDA
AspenBio Pharma, AppyScore

SAN DIEGO, Aug. Twenty one (HSMN NewsFeed) — Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") t…
Regenerative Medicine, Neurology, FDA
Stemedica Cell Technologies, mesenchymal bone marrow, ischemic stroke, stem cell

West Chester (PA), Exton (PA), USA, Aug 20 –(HSMN NewsFeed)– Synthes, Inc. (SWX:SYST.VX), a major global laboratory device company in the orthopaedic trauma, spine, and cranio-maxillofacial markets, and Kensey Nash Corporation (NASDQ:KNSY), a big deve…
Devices, Regenerative Medicine
Synthes, Kensey Nash, extracellular matrix